Clinical trial
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256 is registered in ClinicalTrials.gov with Syndax Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Syndax Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 11, 2023
- Completion date
- November 30, 2026
- Enrollment
- 145 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.